title: [Implementation of the neonatal cystic fibrosis screening program in Switzerland: beginning January 2011].
abstract: The diagnosis of cystic fibrosis (CF) is often delayed because of the nonspecificity of a wide variety of clinical symptoms at disease onset. Newborn screening for CF has been advocated to reduce delays in diagnosis, facilitating preventive care for early respiratory and nutritional involvement. According to American and European consensus and experience of existing programs, a Swiss Nationwide Cystic Fibrosis Newborn Screening Program started in January 2011. Screening strategy combines two steps: an immunoreactive trypsinogen assay and DNA mutation analysis in dried blood samples at day 4 (Guthrie cards).
authors: Unité de pneumologie pédiatrique, Hôpital des enfants, Rue Willy Donzé 6, 1211 Geneve 14. anne.mornand@hcuge.ch
authors: Anne
authors: A
authors: Mornand
authors: Jürg
authors: J
authors: Barben
authors: Gaudenz
authors: G
authors: Hafen
mesh_terms: D003550:Cystic Fibrosis / Q000097:blood / Q000175:diagnosis* / Q000235:genetics / Q000517:prevention & control; D004252:DNA Mutational Analysis; D006801:Humans; D007231:Infant, Newborn; D015997:Neonatal Screening; D011237:Predictive Value of Tests; D012680:Sensitivity and Specificity; D013557:Switzerland; D014362:Trypsinogen / Q000097:blood*
chemical_list: D014362:Trypsinogen